Study shows life-saving benefit of baricitinib for ventilated COVID patients

Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation (ECMO) lived more often when randomized to receive baricitinib. Doctors call this drug ‘bari,’ and receiving the pill once a day for up to 14 days yielded one of the largest a survival advantages seen yet in the COVID pandemic, according to a study published in The Lancet Respiratory Medicine.